Per the terms of the Clinical Co-Development Agreement, the Company agreed to reimburse AgonOx up to $ 4,000,000 in expenses incurred to conduct a Phase 1 clinical trial of PH- 762 treated DP TIL in …
On April 8, 2026, Phio Pharmaceuticals Corp. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Sales Agent…
the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 862,500 shares of Common Stock
Advirna assigned to the Company its existing patent and technology rights related to the INTASYL technology in exchange for an annual maintenance fee of $ 100,000
Phio Pharmaceuticals Corp. Customers
No clients on recordNo downstream customers found in our database for Phio Pharmaceuticals Corp..
Phio Pharmaceuticals Corp. Debt Obligations
Instrument
Description
Confidence
Evidence
PHIO-DEBT-11769
Warrants outstanding: 2.86
90%
xbrl warrant detail from xbrl 2026-03-31.
PHIO-DEBT-11770
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
Phio Pharmaceuticals Corp. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Phio Pharmaceuticals Corp..
Phio Pharmaceuticals Corp. Ownership
Holder
Name
Confidence
Evidence
PHIO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 25 tracked holders.
